Dominique Verhelle

The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies

Bhavatarini Vangamudi, Thomas A. Paul, Parantu K. Shah et al. · Cancer Research · 2015 · 266 citations · Full text

Atpase Domain, Exclusive Catalytic Subunits, Drug Target +17

Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34+ Progenitor Cells

Dominique Verhelle, Laura G. Corral, Kevin Wong et al. · Cancer Research · 2007 · 231 citations

Hematological Malignancy, Malignant B Cells, Bone Marrow Function +13

Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells

Laure A Moutouh-de Parseval, Dominique Verhelle, Emilia Glezer et al. · Journal of Clinical Investigation · 2008 · 178 citations · Full text

Bone Marrow Failure, Sickle-cell Disease, Heme Homeostasis +15

Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism

Laure Escoubet‐Lozach, I-Lin Lin, Kristen Jensen-Pergakes et al. · Cancer Research · 2009 · 170 citations · Full text

Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (<i>R</i>)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (PF-06821497)

Pei‐Pei Kung, Patrick Bingham, Alexei Brooun et al. · Journal of Medicinal Chemistry · 2017 · 125 citations · Full text